The authors declare that they have no competing interests.
Genetic variants in the integrin gene predicted microRNA-binding sites were associated with the risk of prostate cancer
Article first published online: 12 OCT 2012
© 2012 Wiley Periodicals, Inc.
Volume 53, Issue 4, pages 280–285, April 2014
How to Cite
Liu, J., Huang, J., He, Y., Liu, J., Liao, B. and Liao, G. (2014), Genetic variants in the integrin gene predicted microRNA-binding sites were associated with the risk of prostate cancer. Mol. Carcinog., 53: 280–285. doi: 10.1002/mc.21973
Jiaming Liu and Jin Huang contributed equally to this work.
Liu JM and Huang J finished genomic DNA extraction, HRM analysis, statistical analysis, and drafted the manuscript. He YZ, Liu JN, Liao BH, and Liao G participated in collecting blood samples and HRM analysis. Huang J conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
- Issue published online: 11 MAR 2014
- Article first published online: 12 OCT 2012
- Manuscript Accepted: 22 SEP 2012
- Manuscript Revised: 3 SEP 2012
- Manuscript Received: 25 FEB 2012
- prostate carcinoma;
- micro-RNA binding sites
microRNAs (miRNA) silence target genes through Watson–Crick based binding to the 3'untranslated regions (3′UTR). Thus, polymorphisms in the miRNA-binding sites may disrupt this process and play a potential role in cancer pathogenesis. Integrins have been implicated in the genesis and development of many tumors. This study was designed to evaluate the association between five SNP loci in predicted miRNA-binding sites in five integrin genes and prostate cancer occurrence and prognosis to provide data for screening high-risk Chinese Han individuals. These five polymorphisms were genotyped by using the high-resolution melting method (HRM) in 347 Chinese Han prostate cancer patients with long-time follow-up together with 367 age-matched healthy controls. GC carriers of rs11902171 in ITGAv were associated with a decreased risk of prostate cancer (OR 0.57, 95% CI 0.35–0.93). However, no significant difference was detected in genotype distributions of the five SNP loci in the progression-free survival time of prostate cancer. The ITGAv gene SNP rs11902171 may be potentially associated with the risk of prostate cancer. © 2012 Wiley Periodicals, Inc.